Disruptive
‍therapies for
‍aging diseases

WHO WE ARE

TOPADUR Pharma AG is a clinical-stage swiss biopharmaceutical start-up based in Schlieren, Zurich.

We strive for significant improvement of patients’ quality of life while providing sustainable high growth value for investors and employees.

About us

WHAT WE DO

The company has discovered the DualTOP™ technology platform consisting of new dual-acting drugs.

We developed an attractive portfolio of drug candidates to address high unmet needs in aging diseases.

Pipeline

WHAT WE SOLVE

We restore healthy blood flow to fight aging diseases.

Our Approach

TOPADUR Pharma AG: From Idea to Solution

We are enhancing quality of life through ground-breaking therapies.

About us

Our dual-mode of action drugs target the cGMP-Enzyme Regulation System.

Our Approach

An overview of the pipeline with our major projects.

Pipeline

cGMP-Enzyme Regulation System

Problem

Aging processes are characterized by a reduction in blood circulation and dysregulation in cell-cell communication. The misbalance of cGMP levels leads to diseases like chronic wounds, skin fibrosis, age-related macula degeneration, diabetic retinopathy, colorectal cancer, hair loss and skin aging.

Solution

TOPADUR designed new drugs that target the cGMP-Enzyme Regulation System. TOPADUR’s compounds regulate the activity of sGC and PDE5 enzymes to increase the level of cGMP. This ultimately enables blood circulation and corrects the insufficient cell-cell communication.

News

15.10.2021
Press Release

EMA grants TOP-N53 Orphan Drug Designation for the Treatment of Digital Ulcers

EMA grants TOP-N53 Orphan Drug Designation for the Treatment of Digital Ulcers in Systemic Sclerosis.

Read more
5.10.2021
Press Release

TOPADUR Pharma AG announces positive results from TOP-N53 First-in-Human Study

TOPADUR Pharma AG announces positive results from a First-in-Human study evaluating the safety, tolerability and efficacy of TOP-N53.

Read more
6.7.2021
Press Release

TOPADUR Pharma AG announces completion of TOP-N53 First-in-Man Study

TOPADUR announces the completion of Phase 1 dose escalation study of TOP-N53, a first-in-class wound healing drug candidate.

Read more
Go to News

What drives us

Jaan
Research & Development

What inspires and excites me about working at Topadur is the drive for innovation and the atmosphere within the team, as well as the versatility of my work.

Giancarlo
IT

Taking part in the development of TOPADUR and seeing its progress motivates me.

Tobias
Research & Development

With a team of highly passionate people with various specialist skills and background, Topadurians develop together innovative therapeutic options with a common goal of helping patients in need.

Michael
Research & Development

TOPADUR’s entrepreneurial spirit enables me to combine conceptual work with practical application in the laboratory and thus create something meaningful.

Rita
Project Management

I am inspired by TOPADUR's commitment to developing new drugs that will have a meaningful impact on peoples’ lives.

Esra
Research & Development

Being part of TOPADUR from the beginning, experiencing its growth and contributing to its success has been a privilege. With exciting projects and results, TOPADUR is an attractive workplace.

Awards